Qualigen Therapeutics, Inc. Announces management changes.

Core Insights - Qualigen Therapeutics, Inc. announced the immediate resignations of CEO Michael Poirier and CFO Christopher Lotz due to disagreements over the company's future direction and strategic initiatives [1] - The board appointed Campbell Becher as President and Kevin Richardson as Interim CEO and CFO, indicating a shift in leadership aimed at enhancing shareholder value [2][3] Leadership Changes - Michael Poirier resigned as CEO and Chairman, effective immediately, along with CFO Christopher Lotz, both citing disagreements with the company's strategic direction [1] - Campbell Becher was appointed as President of the company on September 25, 2024, effective immediately [2] - Kevin Richardson was appointed as Interim CEO and CFO, bringing extensive experience in leading strategic initiatives in small cap companies [3] Future Outlook - Both new leaders, Richardson and Becher, expressed enthusiasm for the company's future and potential opportunities, indicating a proactive approach to upcoming strategic initiatives [3][4]